Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia

American Journal of Hematology

Volumn 88, Issue 8, 2013, Pages 642-646

  Brunner, Andrew M ^a   Sadrzadeh, Hossein ^a   Feng, Yang ^b   Drapkin, Benjamin J ^a   Ballen, Karen K ^a   Attar, Eyal C ^a   Amrein, Philip C ^a   Mcafee, Steven L ^a   Chen, Yi Bin ^a   Neuberg, Donna S ^b   Fathi, Amir T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMONAFIDE; CYTARABINE; DAUNORUBICIN; IDARUBICIN; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BODY MASS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CAUCASIAN; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; GERIATRIC PATIENT; GROUPS BY AGE; HUMAN; INDUCTION CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; BODY MASS INDEX; CORONARY ARTERY DISEASE; CYTARABINE; DIABETES MELLITUS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 84880790012     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23462     Document Type: Article

References (44)

1. Estey E, Döhner H. Acute myeloid leukaemia. Lancet 2006;368:1894-1907.
2. Walter RB, Othus M, Borthakur G, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: A novel paradigm for treatment assignment. JCO 2011;29:4417-4424.
3. Juliusson G, Antunovic P, Derolf Å, et al. Age and acute myeloid leukemia: Real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009;113:4179-4187.
4. Krug U, Röllig C, Koschmieder A, et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: A web-based application for prediction of outcomes. Lancet 2010;376:2000-2008.
5. Fröhling S, Schlenk RF, Kayser S, et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: Results from AMLSG trial AML HD98-B. Blood 2006;108:3280-3288.
6. Söderberg KC, Kaprio J, Verkasalo PK, et al. Overweight, obesity and risk of haematological malignancies: A cohort study of Swedish and Finnish twins. Eur J Cancer 2009;45:1232-1238.
7. Lichtman MA. Obesity and the risk for a hematological malignancy: Leukemia, lymphoma, or myeloma. Oncologist 2010;15:1083-1101.
8. MacInnis RJ, English DR, Hopper JL, et al. Body size and composition and the risk of lymphohematopoietic malignancies. J Natl Cancer Inst 2005;97:1154-1157.
9. Ross JA, Parker E, Blair CK, et al. Body mass index and risk of leukemia in older women. Cancer Epidemiol Biomarkers Prev 2004;13:1810-1813.
10. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U. S. adults.N Eng J Med 2003;348:1625-1638
11. Larsson SC, Wolk A. Overweight and obesity and incidence of leukemia: A meta-analysis of cohort studies. Int J Cancer 2008;122:1418-1421.
12. Inaba H, Surprise HC, Pounds S, et al. Effect of body mass index on the outcome of children with acute myeloid leukemia. Cancer 2012;118:5989-5996.
13. Lange BJ, Gerbing RB, Feusner J, et al. Mortality in overweight and underweight children with acute myeloid leukemia. JAMA 2005;293:203-211.
14. Bulley S, Gassas A, Dupuis LL, et al. Inferior outcomes for overweight children undergoing allogeneic stem cell transplantation. Br J Haematol 2008;140:214-217.
15. Barker CC, Agovi M-A, Logan B, et al. Childhood obesity and outcomes after bone marrow transplantation for patients with severe aplastic anemia. Biol Blood Marrow Transplant 2011;17:737-744.
16. Medeiros BC, Othus M, Estey EH, et al. Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia. Haematologica 2012;97:1401-1404.
17. Lee HJ, Licht AS, Hyland AJ, et al. Is obesity a prognostic factor for acute myeloid leukemia outcome? Ann Hematol 2012;91:359-365.
18. Carson KR, Bartlett NL, McDonald JR, et al. Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma. JCO 2012;30:3217-3222.
19. Navarro WH, Agovi M-A, Logan BR, et al. Obesity does not preclude safe and effective myeloablative hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML) in adults. Biol Blood Marrow Transplant 2010;16:1442-1450.
20. Navarro WH. Impact of obesity in the setting of high-dose chemotherapy. Bone Marrow Transplant 2003;31:961-966.
21. Navarro WH, Loberiza FR, Jr, Bajorunaite R, et al. Effect of body mass index on mortality of patients with lymphoma undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2006;12:541-551.
22. Ogden CL Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006;295:1549-1555.
23. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: Determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010;116:354-365.
24. Gehan EA, George SL. Estimation of human body surface area from height and weight. Cancer Chemother Rep 1970;54:225-235.
25. Mosteller R. Simplified calculation of body-surface area. N Engl J Med 1987;317:1098-1098.
26. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood 2005;106:2912-2919.
27. Tilg H, Moschen AR. Adipocytokines: Mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006;6:772-783.
28. Tamburini J, Chapuis N, Bardet V, et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: Rationale for therapeutic inhibition of both pathways. Blood 2008;111:379-382.
29. Chapuis N, Tamburini J, Cornillet-Lefebvre P, et al. Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: Therapeutic value of neutralizing anti-IGF-1R antibody. Haematologica 2010;95:415-423.
30. Bruserud O, Huang TS, Glenjen N, et al. Leptin in human acute myelogenous leukemia: Studies of in vivo levels and in vitro effects on native functional leukemia blasts. Haematologica 2002;87:584-595.
31. Hino M, Nakao T, Yamane T, et al. Leptin receptor and leukemia. Leuk Lymphoma 2000;36:457-461.
32. Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. JCO 2012;30:1553-1561.
33. Hunter RJ, Navo MA, Thaker PH, et al. Dosing chemotherapy in obese patients: Actual versus assigned body surface area (BSA). Cancer Treat Rev 2009;35:69-78.
34. Rodvold KA, Rushing DA, Tewksbury DA. Doxorubicin clearance in the obese. JCO 1988;6:1321-1327.
35. Nakao T, Hino M, Yamane T, et al. Expression of the leptin receptor in human leukaemic blast cells. Br J Haematol 1998;102:740-745.
36. Ritzmo C, Söderhäll S, Karlén J, et al. Pharmacokinetics of doxorubicin and etoposide in a morbidly obese pediatric patient. Pediatr Hematol-Oncol 2007;24:437-445.
37. Löwenberg B, Ossenkoppele GJ, Van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009;361:1235-1248.
38. Supino R, Necco A, Dasdia T, et al. Relationship between effects on nucleic acid synthesis in cell cultures and cytotoxicity of 4-demethoxy derivatives of daunorubicin and adriamycin. Cancer Res 1977;37:4523-4528.
39. Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991;77:1666-1674.
40. Fernberg P, Odenbro Å, Bellocco R, et al. Tobacco use, body mass index, and the risk of leukemia and multiple myeloma: A Nationwide Cohort Study in Sweden. Cancer Res 2007;67:5983-5986.
41. Green AS, Chapuis N, Maciel TT, et al. The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. Blood 2010;116:4262-4273.
42. Li D. Metformin as an antitumor agent in cancer prevention and treatment. J Diabetes 2011;3:320-327.
43. Griggs JJ, Sorbero ME, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med 2005;165:1267-1273.
44. Davies BJ, Walsh TJ, Ross PL, et al. Effect of BMI on primary treatment of prostate cancer. Urology 2008;72:406-411.